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dampness-heat retention according to Traditional Chinese
Medicine (TCM) theory.
Methods: A total of 96 patients who were HBsAg and
HBVDNA positive and differentiated as TCM syndrome
pattern of liver depression and spleen asthenia accompanied
by dampness-heat retention were enrolled. They were
randomized to receive either JianpiQinghua Prescription
Combined with Lamivudine or lamivudine 100mg daily or
JianpiQinghua Prescription Rate of HBVDNA loss, change of
HBVDNA load, indicators of liver function and symptoms
and signs were observed in all patients for 2 years. HBVDNA
drew from sera of patients who were HBVDNA positive at
different periods of treatment of JianpiQinghua Prescription
Combined with Lamivudine or lamivudine alone, were
ampliﬁed by polymerase chain reaction, then adopted
caliper1000 micro slow chip technique to determine HBV
YMDD mutants.
Results: At the end of the 2nd year, 81.3% of JianpiQinghua
Prescription Combined with Lamivudine recipients had
undetectable serum HBVDNA, compared with 48.4%
and 40.0% of those in the lamivudine 100mg daily
or JianpiQinghua Prescription. Rate of HBeAg/anti-HBe
seroconversion were 42.1% vs 23.8%.20.8%. ALT levels were
remained in normal ranges in 96.3% and 71.4% of whose ALT
were abnormal before treatment in the treated group and
lamivudine control group respectively. At the end of the 2nd
year, 93.8% vers 58.1% and 46.7% of patients in the treated
group and the control groups respectively achieved total
respond rate, there were signiﬁcant difference between the
three groups. By the end of 2 years, HBV YMDD mutation in
the treated group was 15.6%, whereas lamivudine controlled
group was 38.7%, there were signiﬁcant difference between
two groups. YMDD mutation in those precore nt1896
mutations seemed to higher than non-precore nt1896
mutations but there was no signiﬁcant difference.The
inﬂuence of HBV genotype to YMDD mutation had not been
proved, the mean HBVDNA levels and serum ALT were higher
in the YMDD mutations than those in non-YMDD mutations,
but still lower than before treatment HBeAg/anti-HBe
seroconversion occurred in the YMDD mutations but lower
than non-YMDD mutations.
Conclusions: HBV replication and YMDD mutation
suppressing as well as liver function and clinical
improvement could be obtained after 2-years combination
therapy of JianpiQinghua Prescription Combined with
Lamivudine of good tolerance and safety. Affecting factors
of hepatitis B virus (HBV) YMDD mutant related to
Lamivudine were:long period of treatment, taller HBVDNA
loads and lower level of serum ALT before treatment,
HBeAg positive, higher body mass index. The better early
virological response can be one of the signiﬁcant predictors
of curative effect for Lamivudine treatment.
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Mechanisms underlying to chronic infection of hepatitis B
virus are not well-understood. Impaired function of
DCs in chronic viral infections has been reported, and
recent reports showed that PD-1 and its cognate ligand
PD-L1 interaction negatively modulates the immunity to
T lymphocyte function. To investigate the immune responses
of DC vaccine to hepatitis B virus after blocking PD-1:PD-L1
pathway with PD-L1 monoclonal neutralizing antibodies
(Abs). We treated HBV transgenic mice (inbred BALB/c)
with blocking Abs speciﬁc for PD-L1, followed by adoptive
transfer of HBsAg-pulsed DCs, which were generated
from BALB/c bone marrow cells.Three and six days after
transfer, Blocking PD-L1 signaling stimulated proliferation
of CD3+CD8+ splenic T lymphocytes more efﬁciently than DC
vaccine treatment alone, coincident elevation of secreting
IFN-g, which was an important antiviral cytokine. In addition
we found that the HBsAg titers in the serum of mice
treated with PD-L1 Abs were dramatically decreased, which
is accompanied with increased levels of ALT. These results
indicate that blocking PD-1:PD-L1 interaction can promote
the proliferation of speciﬁc CD3+CD8+ T lymphocytes
proliferation and stimulate the secretion of IFN-g, which
synergistically improves the function of inhibiting HBV in
transgenic mice induced by HBsAg-pulsed DC vaccine. DCs
pulsed by HBsAg in combination with anti-PD-L1 Abs thus
may be a promising approach for therapeutic vaccination to
hepatitis B virus.
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Background: Tumor necrosis factor-a (TNF-a) plays a pivotal
role in the viral clearance and host immune response to
HBV, and the capacity for TNF-a production in individuals
is inﬂuenced by a major genetic component. The studies
of TNF-a-308 gene promoter polymorphism in chronic HBV
infection have reported apparently conﬂicting results.
Objective: We did meta-analysis on TNF-a genetic variants
to derive a more precise estimation of the relationship
between the polymorphism of TNF-a-308 gene promoter
and chronic HBV infection.
Method: Meta-analysis was done of 22 case-control studies
in relation to TNF-a-308 gene promoter, involving a total
of 4338 chronic HBV infection cases and 3013 controls.
The pooled odds ratios (ORs) for the risk associated with
the genotypes of GA, AA, and GA+AA (A-allele carriers)
compared with the GG genotype were calculated.
Results: Overall meta-analysis indicated that 308A
heterozygotes (GA) had a roughly 22% decreased risk of
developing CHB with a borderline signiﬁcance (OR = 0.78;
95%CI: 0.60 1.02; P = 0.065). For the 308A allele
homozygotes (AA) and carriers (GA+AA), the pooled ORs
both indicated a signiﬁcantly decreased risk of CHB
(OR = 0.39; 95%CI: 0.21 0.73; P = 0.003; and OR= 0.74;
95%CI: 0.57 0.96; P = 0.026, respectively) (Table 1). In the
subgroup analyses by ethnicity, signiﬁcantly decreased risks
were associated with 308 variant genotypes (GA and AA) in
Mongoloid populations in all genetic models. However, no
signiﬁcant associations were found in Caucasoid.
Conclusion: The meta-analysis suggests that the
TNF-a 308A allele is a low-penetrant protective factor for
chronic HBV infection, especially in Mongoloid.
Table 1. Main results of pooled ORs in the meta-analysis
GA vs GG AA vs GG GA + AA vs GG
OR (95%CI) P P
(Q-test)
OR (95%CI) P P
(Q-test)
OR (95%CI) P P
(Q-test)
Total 0.78
(0.60, 1.02)
0.065 0.0001 0.39
(0.21, 0.73)
0.003 0.094 0.74
(0.57, 0.96)
0.026 0.0001
Mongoloid 0.71
(0.49, 1.04)
0.078 0.0001 0.18
(0.11, 0.31)
0.0001 0.440 0.66
(0.46, 0.95)
0.026 0.0001
Caucasoid 0.91
(0.73, 1.14)
0.408 0.185 0.93
(0.43, 1.99)
0.842 0.672 0.91
(0.73, 1.13)
0.409 0.121
SR 0.67
(0.50, 0.89)
0.006 0.080 0.31
(0.17, 0.54)
0.0001 0.159 0.65
(0.49, 0.86)
0.003 0.062
Healthy 0.88
(0.59, 1.34)
0.559 0.0001 0.40
(0.16, 1.01)
0.054 0.098 0.82
0.54, 1.24)
0.347 0.0001
Note: P(Q-test): P value of Q-test for heterogeneity test.
A random-effects model was used when P value for heterogeneity test <0.1; otherwise, a ﬁxed-effects
model was used.
